📉 The Financial Deep Dive
Sai Life Sciences Limited has unveiled robust financial results for the quarter and nine months ending December 31, 2025, showcasing significant year-on-year (YoY) expansion.
The Numbers:
- Consolidated Revenue: For the quarter, revenue from operations surged by 26.53% YoY to ₹5,564.64 million. The nine-month period saw revenue grow by 42.62% YoY to ₹15,903.53 million.
- Consolidated Profit After Tax (PAT): PAT experienced a remarkable increase of 86.39% YoY for the quarter, reaching ₹1,003.75 million. For the nine months, PAT skyrocketed by 198.33% YoY to ₹2,446.74 million.
- Standalone Performance: Standalone revenue and PAT mirrored this strong trend, with Q3 PAT up 91.22% YoY and nine-month PAT up 186.10% YoY.
- Earnings Per Share (EPS): Diluted EPS for the consolidated quarter stood at ₹4.71, a notable increase from ₹2.84 in the prior year period. For the nine months, diluted EPS was ₹11.53, up from ₹4.31 YoY.
The significant YoY PAT growth is a testament to operational leverage and demand. However, an exceptional item of loss amounting to ₹82.93 million was recognized in the current quarter and nine-month period. This relates to the financial implications arising from the enactment of new Labour Codes, specifically impacting gratuity and leave liabilities, and has been classified by the company as a non-recurring event.
The statutory auditors, M/s. Deloitte Haskins & Sells LLP, have reviewed the results and issued an unmodified conclusion for both standalone and consolidated financial statements, indicating a clean review.
The Grill:
No aggressive analyst questions or controversial management commentary were present in the provided filing.
🚩 Risks & Outlook
The primary factor for investors to note is the ₹82.93 million one-off loss impacting the current quarter's profitability. While the company has classified this as non-recurring due to new Labour Codes, its precise long-term effect on operational costs needs monitoring.
Beyond this, the strong YoY growth in revenue and PAT, coupled with an unmodified audit report, presents a positive outlook. The approval of employee stock options (205,000 ESOPs) under the management scheme is a standard practice for incentivizing personnel. Investors will watch for continued revenue expansion and sustained profitability in subsequent quarters.